Business
Co-Diagnostics, Inc. Logix Smart™ COVID-19 Test Authorized for Use in Australia
SALT LAKE CITY, Aug. 7, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the
About this update from Co-diagnostics, Inc.
[{"type":"text","content":"SALT LAKE CITY, Aug. 7, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Australia has been added to the list of countries that have authorized the Logix Smart™ COVID-19 for use in detecting SARS-CoV-2, the virus that causes COVID-19.\n\n \n \n \n \n \n \n\n \nAustralia joins the United States, India, Mexico, the European Community and others as a region where the Company's test can be sold and used as a coronavirus in vitro diagnostic (IVD). The Australian Government Register of Therapeutic Goods Certificate was recently issued to the Company's distributor in Australia, approving the distributor to supply the Class 3 IVD to the Australian market.\nDwight Egan, CEO of Co-Diagnostics, commented, \"Co-Diagnostics recognizes the importance of accurate, high-throughput testing in combating surges of coronavirus infections, and we are gratified that our test is being used to help people in so many countries to safely navigate this ongoing pandemic, now also including Australia.\"\nThe news follows recent reports of a soaring coronavirus outbreak in Melbourne, prompting the state of Victoria to declare a \"state of disaster\" and to strengthen lockdown measures.\nThe CE-marked and FDA EUA Co-Diagnostics Logix Smart COVID-19 test is currently available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA), and is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes COVID-19, in the US and many other countries. \nAbout Co-Diagnostics, Inc.:Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.\nForward-Looking Statements:This press release contains forward-looking statements. Forward-looking statements can be identified by words such as \"believes,\" \"expects,\" \"estimates,\" \"intends...